Home › What Pharma/Biotech Investors Need To Know About Adaptive Trials
 

Keywords :   


What Pharma/Biotech Investors Need To Know About Adaptive Trials

2016-01-16 19:10:13| Biotech - Topix.net

The FDA allows for adaptive drug trials during which key protocols may be altered during the course of the trial depending on interim results. Investors concerned with pharmaceutical or biotech drug development, from early to late stages, need to be aware of the benefits and risks of adaptive trials because their use and interpretation can impact corporate valuations.

Tags: investors trials adaptive pharmabiotech

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
16.05Who is Paula Vennells? Ex-Post Office boss in Horizon IT inquiry
16.05BASF Expands Biomass Balance Portfolio for Selected Chemical Intermediates
16.05INDA Releases 11th Annual North America Supply Report
16.05Dow and SCGC Partner to Change 200KTA of Plastic Waste Into Circular Products
16.05Leanpath Uses Generative AI to Drive Action on Food Waste Data
16.05AkzoNobels Como Site Achieves Highest Automotive Industry Quality Certification
16.05ECONWARDs Counterplan for Landfill-Bound Organics
16.05Mortgage rates cut but borrowing pressures remain
More »